Thrombophilia and Thrombosis in Behçet's Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorAtaturk University

About this trial

Behçet's disease (BD) is a systemic vasculitis of unknown cause, affecting mainly young adults. Vasculopathy has been reported in 16.8-51.5% of cases. Genetic, infectious factors, environmental factors, presence of autoantibodies, endothelial pathologies and hypercoagulability are responsible for the etiopathogenesis of BD. The main involvements responsible for morbidity and mortality in Behçet's disease are ocular, major cardiovascular and neurological involvements. Although there is an increased thrombotic risk in the etiopathogenesis of Behçet's disease, the cellular and molecular mechanisms are not fully understood. Although endothelial dysfunction due to inflammation has been shown to be the primary cause of vascular damage in Behçet's disease, some clinical evidence suggests that hypercoagulable states also contribute to thrombosis. The most common form of vascular involvement in Behçet's disease is deep vein thrombosis in the lower extremities. Arterial occlusion mostly affects the subclavian and pulmonary arteries. Although arterial involvement is rarer than venous involvement in Behçet's disease, morbidity and mortality are higher than venous involvement.

Although an increased thrombotic risk is mentioned in the etiopathogenesis of Behçet's disease, it is still controversial whether vasculitis or susceptibility to hypercoagulability plays a role in the pathogenesis of venous thrombosis. In addition, there are very few studies in the literature in which all thrombophilic parameters were analysed. Again, there is no recent study on this subject. The aim of our study is to determine the risk of hypercoagulability in Behçet's disease patients with vascular involvement, which has a highly mortal course.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

18-70 years old

Patients who fulfil the international diagnostic criteria for Behçet's disease

Those who accepted the consent form

Disqualifiers

Those under 18 years of age

accompanied by another inflammatory dermatological disease

Pregnancy and breastfeeding

Those who use drugs that increase the tendency to thrombosis -

Trial population

100 patients with Behçet's disease aged 18-70 years and 100 age- and sex-matched healthy controls

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Blood collection

    Diagnostic test

    Blood collection

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Cases with Behcet's disease1 intervention
Group B: healthy individuals1 intervention

Trial outcomes

Primary outcomes

1

Faktor II G20210A kit

Faktor II G20210A at 200 participants

Time frame
15 months
2

Faktor V Leiden kit

Faktor V Leiden at 200 participants

Time frame
15 months
3

G1691A kit

G1691A at 200 participants

Time frame
15 months
4

MTHFR (Methylene Tetra Hydro Folate Reductase) kit

MTHFR (Methylene Tetra Hydro Folate Reductase) at 200 participants

Time frame
15 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.